-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$42.67127.57% Upside
Cartesian Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Cartesian Therapeutics, Inc.?
Cartesian Therapeutics, Inc. has been rated by research analysts at H.C. Wainwright, Canaccord Genuity, Mizuho Securities in the past 90 days.